Shi-Yong Sun, PhD

Department of Hematology and Medical Oncology, Emory Winship Cancer Institute and Emory University School of Medicine, Atlanta, GA, USA

Dr. Sun earned his Ph.D. in cancer pharmacology from Peking Union Medical College (PUMC)/Chinese Academy of Medical Sciences (CAMS) in 1990 and late received his postdoctoral training in cancer biology at the University of Texas M.D. Anderson Cancer Center in Houston, Texas, USA. Dr. Sun is currently a tenured Professor in the Department of Hematology and Medical Oncology at the Emory University School of Medicine and Winship Cancer Institute in Atlanta, Georgia, USA. He is also a Georgia Research Alliance Distinguished Cancer Scientist and Halpern Research Scholar. Dr. Sun’s research primarily focuses on the following areas: 1) regulation of death receptors, particularly TRAIL receptors, by small therapeutic molecules and their implications in drug-induced apoptosis and cancer therapy; 2) understanding mTOR signaling in cancer and targeting the mTOR axis for cancer therapy; and 3) understanding and overcoming acquired resistance to third generation EGFR inhibitors. He is on the editorial boards of over 25 cancer-related journals, reviewed manuscripts for over 75 scientific journals and grants for over 10 international organizations and has published over 150 original research papers in prominent peer-reviewed journals.